1
项与 CALRLong36 peptide(Herlev Hospital) 相关的临床试验A Phase-1-first in Man Study in Patients With CALR-mutant Myeloproliferative Neoplasms by Vaccinating With CALR Exon 9 Mutant Peptide
A phase-I-first in man study in patients with calreticulin(CALR)-mutant MPN by vaccinating with exon 9 mutated peptide with the adjuvant Montanide ISA-51 to monitor safety and toxicity and the immunological response to vaccination.
100 项与 CALRLong36 peptide(Herlev Hospital) 相关的临床结果
100 项与 CALRLong36 peptide(Herlev Hospital) 相关的转化医学
100 项与 CALRLong36 peptide(Herlev Hospital) 相关的专利(医药)
100 项与 CALRLong36 peptide(Herlev Hospital) 相关的药物交易